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http://dx.doi.org/10.1053/j.gastro.2016.07.038BACKGROUND & AIMS: Studies are needed to determine the
optimal regimen for patients with chronic hepatitis C virus
(HCV) genotype 2, 3, 4, or 6 infections whose prior course of
antiviral therapy has failed, and the feasibility of shortening
treatment duration. We performed a phase 2 study to deter-
mine the efﬁcacy and safety of the combination of the nucle-
otide polymerase inhibitor sofosbuvir, the NS5A inhibitor
velpatasvir, and the NS3/4A protease inhibitor GS-9857
in these patients. METHODS: We performed a multicenter,
open-label trial at 32 sites in the United States and 2 sites in
New Zealand from March 3, 2015 to April 27, 2015. Our study
included 128 treatment-naïve and treatment-experienced
patients (1 with HCV genotype 1b; 33 with HCV genotype 2;
74 with HCV genotype 3; 17 with genotype HCV 4; and 3 with
HCV genotype 6), with or without compensated cirrhosis. All
patients received sofosbuvir-velpatasvir (400 mg/100 mg
ﬁxed-dose combination tablet) and GS-9857 (100 mg) once
daily for 6–12 weeks. The primary end point was sustained
virologic response 12 weeks after treatment (SVR12).
RESULTS: After 6 weeks of treatment, SVR12s were achieved
by 88% of treatment-naïve patients without cirrhosis (29 of 33;
95% conﬁdence interval, 72%–97%). After 8 weeks of treat-
ment, SVR12s were achieved by 93% of treatment-naïve
patients with cirrhosis (28 of 30; 95% CI, 78%–99%). After 12
weeks of treatment, SVR12s were achieved by all treatment-
experienced patients without cirrhosis (36 of 36; 95% CI,
90%–100%) and 97% of treatment-experienced patients with
cirrhosis (28 of 29; 95% CI, 82%–100%). The most common
adverse events were headache, diarrhea, fatigue, and nausea.
Three patients (1%) discontinued treatment due to adverse
events. CONCLUSIONS: In a phase 2 open-label trial, we foundsofosbuvir-velpatasvir plus GS-9857 (8 weeks in treatment-
naïve patients or 12 weeks in treatment-experienced patients)
to be safe and effective for patients with HCV genotype 2, 3, 4,
or 6 infections, with or without compensated cirrhosis.
ClinicalTrials.gov ID: NCT02378961.Keywords: Clinical Trial; Direct-Acting Antiviral; DAA; Non-Ge-
notype 1 HCV.
t is estimated that at least 80–185 million people areIchronically infected with the hepatitis C virus (HCV)
worldwide.1–3 Although genotype 1 HCV is the most com-
mon strain of the virus, genotypes 2–6 cumulatively account
for more than half of those infected worldwide, or approx-
imately 60 million people.1 The global prevalence of these
HCV genotypes varies widely, and they are characterized by
differential rates of disease progression, hepatocellular
carcinoma risk, and response to treatment.2 Across the
world, genotype 3 HCV is the second most common strain,
representing 30% of HCV infections, followed by genotype 2
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R(9%), genotype 4 (8%), genotype 6 (5%), and genotype 5
(1%).1 Regimens of recently approved direct-acting antiviral
agents (DAAs) have been shown to provide high rates of
sustained virologic response (SVR) in patients infected by
any of the 6 genotypes.4,5 A small proportion of patients,
however, do not achieve SVR with existing regimens,
particularly those who have previously failed treatment
with a prior DAA agent, in whom resistance-associated
substitutions (RASs) may have emerged to ﬁrst-generation
NS3/4A and NS5A inhibitors.6 Retreatment options for
these patients are limited. One possible retreatment strategy
to address this growing unmet need is to combine 3 highly
potent DAAs with different mechanisms of action that retain
antiviral activity against these emergent RASs. Such a 3-DAA
combination regimen might also allow for the shortening of
treatment duration to <12 weeks in patients who have not
been treated previously for HCV, and improvement of efﬁ-
cacy for patients with genotype 3 and cirrhosis, which is a
more difﬁcult-to-treat population with current therapies.7–9
Sofosbuvir is a nucleotide analogue inhibitor of the HCV
NS5B polymerase approved for the treatment of genotypes
1–4 HCV infection in combination with other agents.10,11
Velpatasvir is a novel HCV NS5A inhibitor with pan-
genotypic efﬁcacy.12 The combination of sofosbuvir and
velpatasvir has been demonstrated in phase 3 clinical trials
to be highly effective and safe in treatment-naïve and pre-
viously treated patients with HCV of all genotypes, including
those with compensated and decompensated cirrhosis.13–15
GS-9857 is a novel macrocyclic NS3/4A protease inhibitor
with potent in vitro antiviral activity against genotypes
1 to 6 HCV and broad coverage of NS3/4A protease
polymorphisms.16–19 In a phase 1 trial, administration of
100 mg GS-9857 to patients with genotype 1–4 HCV resul-
ted in median maximum reductions in HCV RNA of 3
log10 IU/mL.16
We assessed the efﬁcacy and safety of 6–12 weeks of
sofosbuvir-velpatasvir plus GS-9857 in treatment-naïve and
previously treated patients with non–genotype 1 HCV,
including those with compensated cirrhosis.Methods
Study Design
This open-label, 2-cohort, phase 2 study was conducted
between March 3, 2015 and April 27, 2015 at 32 sites in the
United States and 2 sites in New Zealand. Cohort 1 enrolled
treatment-naïve patients and cohort 2 enrolled treatment-
experienced patients. All patients received sofosbuvir-
velpatasvir plus GS-9857.Cohort 1
Treatment-naïve patients in cohort 1 without cirrhosis
received 6 weeks of treatment, while patients with cirrhosis
received 8 weeks of treatment. The protocol speciﬁed that if the
rate of relapse among treatment-naïve patients with cirrhosis
who received 8 weeks of treatment was 10%, another group
could optionally be enrolled to receive 6 weeks of treatment.
This option was not exercised.Cohort 2
Cohort 2 consisted of treatment-experienced patients,
including those who had been treated with DAAs, with or
without interferon. Regardless of cirrhosis status, all patients
received 12 weeks of treatment. If the relapse rate of cohort 2
was 10%, another group could optionally be enrolled to
receive 8 weeks of treatment. This option was not exercised.Patients
Enrollment was open to patients at least 18 years of age
chronically infected with genotypes 2, 3, 4, 5, or 6 HCV with
serum HCV RNA viral loads of at least 10,000 IU/mL. Target
enrollment for patients with genotype 3 HCV was 50% in each
treatment group. Given the low prevalence of genotypes 4, 5, or
6 HCV infections in the United States, there were no minimum
enrollment criteria for these patients. Cirrhosis was deﬁned as
any one of the following: biopsy showing cirrhosis (Metavir
score of 4 or Ishak score of 5), transient elastography
(FibroScan) result of >12.5 kPa, or a FibroTest score of >0.75,
together with an aspartate transaminase to platelet ratio index
of >2 during screening. Exclusion criteria included platelet
count <50,000 cells/mL, hemoglobin <110 g/L for women and
<120 g/L for men, albumin <30 g/L, creatinine clearance <60
mL/min as calculated by the Crockoft-Gault equation, and
prothrombin time or direct bilirubin of <1.5 times the upper
limit of normal. Patients with evidence of decompensation (ie,
clinical ascites, encephalopathy, or variceal hemorrhage) and
those with hepatocellular carcinoma were excluded.
Written informed consent was obtained from all patients
before enrollment and before any study procedures were un-
dertaken. The study was approved by the Institutional Review
Board or independent ethics committees at all participating
sites and was conducted in accordance with the principles of
the Declaration of Helsinki and Good Clinical Practice. The
sponsor (Gilead Sciences) collected the data, monitored the
study conduct, and performed the statistical analyses.Procedures
All patients received a ﬁxed-dose combination tablet of
sofosbuvir 400 mg and velpatasvir 100 mg once daily, along
with a 100 mg tablet of GS-9857 once daily, taken with food.Randomization and masking
This was a nonrandomized, open-label study. Investigators
at the study centers enrolled patients until the target enroll-
ment was reached, including minimum numbers of patients
with genotype 3 HCV infection. No participants or study
personnel were blinded to treatment assignments at any time
during the study.Assessments
Serum HCV RNA concentrations were measured using the
COBAS AmpliPrep/COBAS TaqMan HCV Test, version 2.0
(Roche, Indianapolis, IN) with a lower limit of quantiﬁcation for
HCV RNA of <15 IU/mL. HCV genotype and subtype was
determined using the Siemens VERSANT HCV Genotype
INNO-LiPA 2.0 assay. For all patients, the interleukin 28B
genotype was determined by polymerase chain reaction
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nucleotide polymorphism.
Deep sequencing of the NS3A, NS5A, and NS5B regions of
the HCV RNA using MiSeq technology (DDL Diagnostic Labo-
ratory, Rijswijk, The Netherlands) was performed at baseline
for all patients and at the time of virologic failure for all pa-
tients who did not achieve sustained virologic response 12
weeks after treatment (SVR12). The resulting sequences were
compared with reference sequences or sequences from base-
line samples in order to determine the prevalence of RASs and
the association of RASs with virologic outcomes. RASs present
at >1% of sequence reads are reported.
Safety was assessed in all patients at all on-treatment visits
and for 30 days after the completion of treatment by physical
examination and review of adverse events and blood samples
for clinical laboratory testing.
Outcomes
The primary efﬁcacy end point of this study was SVR12
(serum HCV RNA <15 IU/mL) in all patients who were enrolled
and received at least 1 dose of study drug. The secondary ef-
ﬁcacy end points included proportion of patients with virologic
failure. The primary safety end point was any adverse event
leading to the permanent discontinuation of study treatment.
Statistical Analysis
For this exploratory phase 2 study, we did not plan or
conduct any inferential statistics. No formal sample sizeFigure 1. Patiencalculations were used to determine the group size of 30. The
SVR12 rate in each of the treatment groups was calculated with
2-sided 95% exact conﬁdence intervals (CIs) based on the
Clopper-Pearson method.
Role of the funding source
The study sponsor oversaw trial management, data collec-
tion, statistical analyses, and the writing and review of the
report. All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.Results
Of the 171 patients screened, 128 were enrolled and
received treatment: 33 treatment-naïve patients without
cirrhosis, 30 treatment-naïve patients with cirrhosis, 36
previously treated patients without cirrhosis, and 29 pre-
viously treated patients with cirrhosis (Figure 1). Reasons
for screen failure are listed in the Supplementary Table 1.
Baseline characteristics of patients are given in Table 1. In
total, the study enrolled, 33 (26%) patients with genotype 2
HCV, 74 (58%) patients with genotype 3 HCV, 17 (13%)
patients with genotype 4 HCV, and 3 (2%) patients with
genotype 6 HCV. No patient with genotype 5 HCV was
enrolled. There was 1 patient who was genotype 1b by LiPA
genotyping assay at screening who was enrolled based on a
history of genotype 6 infection, as allowed per protocol; this
was a treatment-naïve patient without cirrhosis whot disposition.
Table 1.Baseline Characteristics
Characteristic
Treatment-naïve Treatment-experienced
No cirrhosis Cirrhosis No cirrhosis Cirrhosis
SOF-VEL þ GS-9857
for 6 wk (n ¼ 33)
SOF-VEL þ GS-9857
for 8 wk (n ¼ 30)
SOF-VEL þ GS-9857
for 12 wk (n ¼ 36)
SOF-VEL þ GS-9857
for 12 wk (n ¼ 29)
Age, y 53 56 57 58
Men, n (%) 12 (36) 21 (70) 26 (72) 21 (72)
Race, n (%)
White 27 (82) 24 (80) 29 (81) 23 (79)
Black 2 (6) 1 (3) 2 (6) 2 (7)
Asian 3 (9) 4 (13) 3 (8) 2 (7)
Other 1 (3) 1 (3) 2 (6) 0
BMI, kg/m2, mean (SD) 26.9 (5.8) 29.8 (5.3) 27.3 (4.9) 30.8 (7.0)
HCV RNA, log10 IU/mL,
mean (SD)
6.2 (0.9) 6.1 (0.7) 6.3 (0.7) 6.4 (0.6)
HCV genotype, n (%)
1b 1 (3)a 0 0 0
2 6 (18) 6 (20) 13 (36) 8 (28)
3 21 (64) 18 (60) 18 (50) 17 (59)
4 5 (15) 5 (17) 4 (11) 3 (10)
6 0 1 (3) 1 (3) 1 (3)
IL28b, n (%)
CC 11 (33) 11 (37) 15 (42) 10 (35)
CT 15 (45) 15 (50) 15 (42) 17 (59)
TT 6 (18) 4 (13) 5 (14) 2 (7)
Missing 1 (3) 0 1 (3) 0
Treatment experience, n (%)
No DAA — — 17 (47) 10 (34)
SOF þ RBV ± PEG 14 (39) 17 (59)
Other DAAs — — 5 (14) 2 (7)
BMI, body mass index; PEG, peginterferon; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir.
aThis patient was enrolled into the study with historical genotype 6, as was allowed by protocol. At screening, the patient was
found to have genotype 1b.
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Rreceived 6 weeks of treatment and achieved SVR12 and will
not be discussed further. The groups were balanced overall,
other than in sex; women made up 64% of treatment-naïve
patients without cirrhosis but only 28%–30% in the other
treatment groups. Among the 65 treatment-experienced
patients in cohort 2, 53% of the 36 without cirrhosis and
66% of the 29 with cirrhosis, patients had previously
received at least 1 DAA. Most treatment-experienced
patients had received sofosbuvir-containing regimens
(Table 1). Details concerning prior HCV treatment regimens
are given in the Supplementary Table 2.
By week 4 of treatment, all 63 treatment-naïve
patients—including those with and without cirrhosis—had
HCV RNA <15 IU/mL. Among treatment-experienced pa-
tients, 11% of those without cirrhosis and 10% of those
with cirrhosis still had detectable HCV RNA (>15 IU/mL) at
week 4 of treatment. By week 8 of treatment, all 65
treatment-experienced patients had undetectable HCV RNA.
Table 2 summarizes information about patients with HCV
RNA <15 IU/mL during and after treatment.
Among treatment-naïve patients, rates of SVR12 were
88% (29 of 33; 95% CI, 72%–97%) in patients without
cirrhosis receiving 6 weeks of treatment, and 93% (28 of
30; 95% CI, 78%–99%) in patients with cirrhosis receiving8 weeks of treatment (Table 2). Treatment-naïve patients
with HCV genotype 3 and cirrhosis who received 8 weeks of
treatment had an SVR12 rate of 94% (17 of 18; 95% CI,
73%–100%).
Among treatment-experienced patients treated for 12
weeks, rates of SVR12 were 100% (36 of 36; 95% CI,
90%–100%) in patients without cirrhosis, and 97% (28 of
29; 95% CI, 82%–100%) in patients with cirrhosis.
Treatment-experienced patients with HCV genotype 3 and
cirrhosis who received 12 weeks of treatment had an SVR12
rate of 94% (16 of 17; 95% CI, 71%–100%). Among patients
who had previously received a DAA, rates of SVR12 were
100% (19 of 19; 95% CI, 82%–100%) in those without
cirrhosis and 95% (18 of 19; 95% CI, 74%–100%) in those
with cirrhosis.
Across the groups, SVR12 rates did not signiﬁcantly vary
by baseline characteristics (Supplementary Table 3). Across
treatment groups, rates of SVR12 were 94% (31 of 33) for
patients with genotype 2 HCV, 97% (72 of 74) for patients
with genotype 3 HCV, and 82% (14 of 17) for patients with
genotype 4 HCV (Table 2). All 3 patients with genotype 6
achieved SVR12.
All 7 patients who did not achieve SVR12 had virologic
relapse (Supplementary Table 4). The highest rates of
Table 2.Patients with Hepatitis C Virus RNA <15 IU/mL During and After Treatment
Variable
Treatment-naïve Treatment-experienced
No cirrhosis Cirrhosis No cirrhosis Cirrhosis
SOF-VEL þ GS-9857
for 6 wk (n ¼ 33)
SOF-VEL þ GS-9857
for 8 wk (n ¼ 30)
SOF-VEL þ GS-9857
for 12 wk (n ¼ 36)
SOF-VEL þ GS-9857
for 12 wk (n ¼ 29)
HCV RNA <LLOQ
During treatment
Wk 2 27 (82) 22 (73) 26 (72) 17 (59)
Wk 4 33 (100) 30 (100) 32 (89) 26 (90)
After treatment
Wk 4 30 (91) 29 (97) 36 (100) 29 (100)
Wk 12 (SVR12) 29 (88) 28 (93) 36 (100) 28 (97)
95% CI 72 to 97 78 to 99 90 to 100 82 to >99
SVR12 by genotype
1b 1a (100) 0 0 0
2 4/6 (67) 6/6 (100) 13/13 (100) 8/8 (100)
3 21/21 (100) 17/18 (94) 18/18 (100) 16/17 (94)
4 3/5 (60) 4/5 (80) 4/4 (100) 3/3 (100)
6 0 1/1 (100) 1/1 (100) 1/1 (100)
Virologic failure
Relapse 4 (12) 2 (7) 0 1 (3)
NOTE. Values are n (%).
LLOQ, lower limit of quantiﬁcation; SOF, sofosbuvir; VEL, velpatasvir.
aThis patient was enrolled into the study with historical genotype 6, as was allowed by protocol. At screening, the patient was
found to have genotype 1b.
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with 12% (4 of 33) of patients without cirrhosis relapsed
after 6 weeks of treatment and 7% of (2 of 30) of patients
with cirrhosis relapsed after 8 weeks of treatment. Among
both groups of treatment-experienced patients receiving
12 weeks of treatment, only one virologic failure was
observed: a 58-year-old white woman with genotype 3a
HCV infection and cirrhosis, who had previously received
unsuccessful treatment with sofosbuvir plus peginter-
feron and ribavirin. This patient, who had HCV RNA <15
IU/mL by week 2 of treatment, had virologic relapse by
post-treatment week 8.Table 3.Sustained Virologic Response 12 Weeks After Treatme
Resistance-Associated Substitutions (1% Sequencing
Variable
Treatment-naïve
No cirrhosis Cirrhosis
SOF-VEL þ GS-9857
for 6 wk (n ¼ 33)
SOF-VEL þ GS-9857
for 8 wk (n ¼ 30)
No RASs 12/12 (100) 16/17 (94)
Any RASs 17/21 (81) 12/13 (92)
NS3 RASs onlya 2/2 (100) 1/1 (100)
NS5A RASs only 8/12 (67) 9/10 (90)
NS5B RASs only 2/2 (100) 1/1 (100)
Multiclass RASsa 5/5 (100) 1/1 (100)
NOTE. Values are n (%).
SOF, sofosbuvir; VEL, velpatasvir.
aIncludes patients with the NS3 RAS Q80K.Baseline sequencing was available for 128 of the 128
patients enrolled in the study. Baseline RASs in at least 1 of
the 3 target genes (NS3, NS5A, and NS5B) were detected by
deep sequencing (1% cutoff) in 63 of the 128 patients: 54%
(34 of 63) treatment-naïve, 26% (7 of 27) interferon-
experienced, DAA-naïve, and 58% (22 of 38) of DAA-
experienced patients (data not shown).
Table 3 shows the SVR rates for patients without RASs
and with single and multi-class NS3, NS5A, and NS5B RASs
with a 1% sequencing cutoff. In treatment-naïve patients,
SVR rates with 8 weeks of treatment with sofosbuvir-
velpatasvir plus GS-9857 were 92% (12 of 13) and 94%nt in Patients With and Without Baseline
Cutoff)
Treatment-experienced SOF-VEL plus GS-9857 for 12 wk
No DAA(s) (n ¼ 27) DAA(s) (n ¼ 38)
20/20 (100) 16/16 (100)
7/7 (100) 21/22 (95)
2/2 (100) 3/3 (100)
2/2 (100) 10/10 (100)
0 3/3 (100)
0 5/6 (83.3)
November 2016 SOF/VEL Plus GS-9857 in HCV GT 2, 3, 4, or 6 Infections 907
CL
IN
IC
AL
LI
VE
R(16 of 17) in patients with and without baseline RASs,
respectively. A 15% sequencing cutoff demonstrates similar
results (Supplementary Table 5).
Sequencing data are available for all 7 virologic failures.
All 6 treatment-naïve patients had the same or fewer to no
RASs detected at time of relapse. The 1 DAA-experienced
patient with genotype 3a who experienced virologic failure
had the NS5A RAS Y93H at baseline and relapse and had
treatment-emergent NS3 RAS Q80R (41%), which does not
confer in vitro resistance to GS-9857 (confers 0.8-fold shift in
50% effective concentration in genotype 3a replicon assays).
Most patients in all 4 groups had at least 1 adverse event
(Table 4). The most common events were headache, diar-
rhea, fatigue, and nausea. All but 3 adverse events were mild
to moderate in severity. The only serious adverse event
reported was gastroenteritis in a treatment-experienced
patient with cirrhosis who received 12 weeks of treatment.
Three patients discontinued treatment due to adverse
events: 2 treatment-naïve and 1 treatment-experienced
patient. All 3 had cirrhosis. One of the treatment-naïve
patients, a 76-year-old Asian woman, discontinued treat-
ment of her own accord due to fatigue on day 36, and the
other, a 64-year-old white woman, had her treatment dis-
continued by the investigator on day 49 due to exacerbation
of diarrhea, vomiting, weakness, and dehydration. The sin-
gle treatment-experienced patient was a 59-year-old blackTable 4.Safety
Variable
Treatment-naïv
No cirrhosis
SOF-VEL þ GS-9857
for 6 wk (n ¼ 33)
SOF-V
for 8
Any AE 23 (70)
Serious AEs 0
AEs leading to treatment
discontinuation
0
Deaths 0
AEs (occurring in 5% of
patients of any cohort)
Headache 10 (30)
Diarrhea 10 (30)
Fatigue 7 (21)
Nausea 9 (27)
Constipation 1 (3)
Dizziness 3 (9)
Dry mouth 2 (6)
Abdominal pain, upper 2 (6)
Nasopharyngitis 1 (3)
Upper respiratory tract infection 2 (6)
Laboratory abnormalities
Hemoglobin, 7.0 to <9.0 g/dL 0
Neutrophils, 500 to <750/mm3 1 (3)
Platelets, 25,000 to <50,000/mm3 0
Creatine kinase, 20.0  ULN 1 (3)
Hyperglycemia, 30 to <40 mg/dL 0
Lipase, <3.0  ULN 0
NOTE. Values are n (%).
AE, adverse event; SOF, sofosbuvir; ULN, upper limit of normawoman who discontinued study treatment of her own
accord after experiencing gastritis on day 64 of treatment.
The adverse events of fatigue and gastritis were considered
unrelated to study drug by the investigator. All 3 patients
who discontinued therapy achieved SVR12.
One patient died during follow-up. This patient, a
treatment-experienced 59-year-old man with genotype 2b
HCV infection without cirrhosis and no cardiac medical his-
tory, died at during post-treatment follow-up week 14. On
the evening before his death, he reported vague epigastric
pain and was found dead the next morning, presumed to
have sudden cardiac death. No autopsy report is available.
The rates of clinically signiﬁcant laboratory abnormalities
were low: 5 patients (4%) had grade 3 abnormalities and 4
(3%) had grade 4 abnormalities. One patient had a grade 4
elevated level of creatine kinase during a follow-up visit. Ac-
cording to the investigator, this patient, a 34-year-old white
manwithout cirrhosiswho received 6weeks of treatment, had
exercised vigorously before the visit. The only laboratory ab-
normalities observed in more than 1 patient were asymp-
tomatic and transient grade 3 and 4 lipase elevations.Discussion
With the recent approval of DAAs, safe and effective
combination regimens are now available for the majority ofe Treatment-experienced
Cirrhosis No cirrhosis Cirrhosis
EL þ GS-9857
wk (n ¼ 30)
SOF-VEL þ GS-9857
for 12 wk (n ¼ 36)
SOF-VEL þ GS-9857
for 12 wk (n ¼ 29)
20 (67) 27 (75) 25 (86)
0 0 1 (3)
2 (7) 0 1 (3)
0 1 (3) 0
3 (10) 11 (31) 8 (28)
1 (3) 10 (28) 8 (28)
3 (10) 10 (28) 6 (21)
3 (10) 8 (22) 4 (14)
2 (7) 2 (6) 1 (3)
0 0 3 (10)
1 (3) 0 3 (10)
1 (3) 1 (3) 1 (3)
1 (3) 0 3 (10)
1 (3) 1 (3) 1 (3)
0 0 1 (3)
0 0 0
0 0 1 (3)
0 0 0
0 1 (3) 0
1 (3) 0 3 (10)
l; VEL, velpatasvir.
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90% can be achieved in most patient populations regardless
of genotype, treatment experience, or presence of cirrhosis.
Although the proportion of patients who do not achieve SVR
with currently approved DAA regimens is small, the abso-
lute number of DAA failures will steadily increase in parallel
with the rate of treatment uptake. DAA failures represent an
unmet medical need without, at this time, any approved
retreatment options. In this open-label, phase 2 study, the
combination of sofosbuvir-velpatasvir plus GS-9857 for 12
weeks was safe and highly effective for the treatment of
patients with genotypes 2, 3, 4, or 6 HCV infection with or
without compensated cirrhosis who were treatment-
experienced, including those who had failed previous DAA
regimens. The high SVR12 rate among treatment-
experienced patients with genotype 3 HCV infection and
cirrhosis is noteworthy, given the lower SVR12 rates
generally experienced by this patient population.
Currently approved regimens for non-genotype 1 HCV
have durations of 12–24 weeks, depending on choice of
regimen and patient’s baseline characteristics, such as HCV
genotype, treatment history, and presence or absence of
cirrhosis. The feasibility of shortening the duration of treat-
ment has been a goal of research, especially for non-ribavirin-
containing regimens. Several trials have evaluated various
combinations of DAAs for 4 weeks, but with uniformly disap-
pointing outcomes—SVR12 rates of 20% to40%.17,20,21 In this
trial, 6 weeks of sofosbuvir-velpatasvir plus GS-9857 achieved
suboptimal results (<90% SVR12 rate) in a historically easy-
to-treat population of treatment-naïve patients without
cirrhosis. Eight weeks of sofosbuvir-velpatasvir plus GS-9857
was safe and effective for treatment-naïve patients with
cirrhosis, including those with HCV genotype 3. Thus, the 8-
week regimen may serve as a shorter-duration option for
treatment-naïve patients with or without cirrhosis and is
currently being evaluated in phase 3 clinical trials.
Additionally, the high SVR12 rates across genotypes sug-
gest the pangenotypic treatment potential of sofosbuvir-
velpatasvir plus GS-9857. Although genotype 1 patients
were not treated in this study, a parallel open-label, phase 2
study of patients infected with HCV genotype 1 was also
conducted,where patients received treatment for 6–12weeks.
This study was limited by its small sample size and
open-label design. Although the ﬁrst phase 2 clinical trial to
evaluate retreatment of non-genotype 1 HCV-infected
patients previously treated with DAA-regimens that
included NS5A inhibitors, only 6 patients in this subgroup
were enrolled. Also, no patients with genotype 5 HCV and
only 3 patients with genotype 6 HCV were enrolled,
reﬂecting the low prevalence of these infections in North
America and New Zealand.
In conclusion, sofosbuvir-velpatasvir plus GS-9857 is a
safe and effective treatment in patients with HCV genotypes
2, 3, 4, and 6, with and without compensated cirrhosis. High
SVR rates were achieved in treatment-experienced patients,
including those with DAA experience, after 12 weeks of
sofosbuvir-velpatasvir plus GS-9857 and in treatment-naïve
patients with compensated cirrhosis after 8 weeks of this
regimen. These 3 potent pangenotypic DAAs have beenco-formulated into a ﬁxed-dose combination tablet. The
phase 3 program will evaluate this ﬁxed-dose combination
for 8 weeks in treatment-naïve patients of all genotypes and
for 12 weeks in patients of all genotypes who had received
previous treatment with a DAA.
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